Article
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
AIDS research and human retroviruses - 1 Feb 2013
Hicks Charles, Clay Patrick, Redfield Robert, Lalezari Jay, Liporace Ralph, Schneider Stefan, Sension Michael, McRae MaryPeace, Laurent Jean-Pierre
Abstract excerpt
Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term risks of adverse events and treatment failure-induced HIV resistance being major concerns. One potential alternative to standard treatment is the use of viral decay accelerators, antiviral agents that theoretically can drive the rate of viral mutation beyond the compensatory capacity of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
